Multiplexed Immunofluorescence (If) Analysis And Gene Expression Profiling Of Biopsies From Patients With Relapsed/Refractory (R/R) Diffuse Large B Cell Lymphoma (Dlbcl) Treated With Lisocabtagene Maraleucel (Liso-Cel) In Transcend Nhl 001 Reveal Patterns Of Immune Infiltration Associated With Durable Response

Background: The availability of chimeric antigen receptor (CAR)-modified T cells (CAR T) has profoundly increased therapeutic options for patients (pts) with B cell malignancies, including DLBCL. Liso-cel is an investigational, anti-CD19, defined composition, 4-1BB, CAR T cell product administered at a target dose of CD4+ and CD8+ CAR T cells. To understand tumor microenvironmental (TME) factors affecting short-term and durable responses in pts with R/R DLBCL who received liso-cel in the TRANSCEND NHL 001 study, we conducted multiplexed IF analyses of 111 DLBCL biopsies for 83 pts obtained at baseline (n=58) and approximately 11 days (D11) (n=53; 28 paired) after liso-cel infusion (NCT02631044).